Enanta Pharmaceuticals (ENTA)
(Delayed Data from NSDQ)
$12.10 USD
+0.43 (3.68%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $12.09 -0.01 (-0.08%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$12.10 USD
+0.43 (3.68%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $12.09 -0.01 (-0.08%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Zacks News
MediWound (MDWD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Enanta Pharmaceuticals (ENTA) Q3 Earnings Expected to Decline
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Enanta Pharmaceuticals (ENTA) Stock Jumps 10.1%: Will It Continue to Soar?
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Enanta's (ENTA) RSV Drug Fails to Meet Study Goal, Stock Drops
by Zacks Equity Research
While a mid-stage study evaluating Enanta's (ENTA) RSV candidate misses out on its primary endpoint, a statistically huge number of subjects achieved undetectable RSV RNA at the end of treatment.
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -13.99% and 8.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Xencor (XNCR) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Xencor (XNCR) delivered earnings and revenue surprises of 155.71% and 302.39%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -30.97% and 3.43%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Why Enanta Pharmaceuticals (ENTA) Might Surprise This Earnings Season
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 6.87% and 33.87%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Enanta Pharmaceuticals (ENTA) This Earnings Season?
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Analysts Estimate Enanta Pharmaceuticals (ENTA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zoetis' (ZTS) Earnings and Revenues Surpass Estimates in Q3
by Kanishka Das
Zoetis' (ZTS) earnings and revenues beat estimates in the third quarter of 2021. The company raised its financial guidance for 2021.
Pacira's (PCRX) Q3 Earnings Beat Estimates, Revenues Miss Mark
by Zacks Equity Research
Pacira's (PCRX) earnings beat estimates in the third quarter of 2021 while revenues miss the same. Its flagship product Exparel's sales rise year over year.
Fulgent Genetics (FLGT) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
The recent buyout of CSI Laboratories and strategic investments in early cancer screening are likely to have contributed to growth for Fulgent Genetics (FLGT).
Zacks Industry Outlook Highlights: Xencor, Enanta, Catalyst Pharmaceuticals, and Molecular Templates
by Zacks Equity Research
Zacks Industry Outlook Highlights: Xencor, Enanta, Catalyst Pharmaceuticals, and Molecular Templates
4 Small Drug Stocks That Hold Promise Despite Industry Challenges
by Kinjel Shah
Some residual impact of the coronavirus pandemic is expected on the Medical-Drugs industry players' third-quarter results. XNCR, ENTA, CPRX and MTEM may prove to be good additions to one's portfolio.
Entasis' (ETTX) Phase III Study on Infection Drug Meets Goal
by Zacks Equity Research
Entasis' (ETTX) phase III ATTACK study achieves primary endpoint. The study evaluates its investigational combo drug SUL-DUR in infections caused by Acinetobacter baumannii.
Enanta Pharmaceuticals (ENTA) Moves 10.6% Higher: Will This Strength Last?
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 15.60% and -1.14%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Enanta Pharmaceuticals (ENTA) Q3 Earnings Expected to Decline
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -15.96% and -21.35%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Enanta Pharmaceuticals (ENTA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 50.00% and 19.26%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Enanta Pharmaceuticals (ENTA) Q1 Earnings Expected to Decline
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 40.22% and -7.80%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?